Appendix Table 8.

Estimated 48-week risks, risk differences and risk ratios of COVID-19 outcomes by NRTI combination in HIV-positive individuals, stratified by sex,^* CoVIHd Collaboration, Spain, February-December 2020

	Documented SARS-CoV-2 infection				Hospitalization due to COVID-19
	No. events	Risks (95% CI), %	Risk Differences (95%CI), %	Risk Ratios (95%CI)	No. events	Risks (95% CI), %	Risk Differences (95%CI), %	Risk Ratios (95%CI)
Men
TAF/FTC	734	4.3 (4.0, 4.6)	0	1.00	126	0.8 (0.7, 1.0)	0	1.00
TDF/FTC	228	4.3 (3.8, 4.9)	0.08 (−0.51, 0.72)	1.02 (0.88, 1.18)	26	0.5 (0.3, 0.8)	−0.29 (−0.56, 0.01)	0.64 (0.40, 1.01)
ABC/3TC	554	5.3 (4.9, 5.8)	1.08 (0.52, 1.60)	1.25 (1.12, 1.39)	123	1.1 (0.9, 1.3)	0.30 (0.06, 0.55)	1.36 (1.06, 1.75)
Other regimes	385	4.7 (4.2, 5.1)	0.40 (−0.15, 0.99)	1.09 (0.97, 1.24)	71	0.7 (0.6, 0.9)	−0.11 (−0.32, 0.13)	0.86 (0.64, 1.18)
Women
TAF/FTC	189	4.6 (4.0, 5.3)	0	1.00	31	0.8 (0.6, 1.2)	0	1.00
TDF/FTC	72	5.0 (3.9, 6.2)	0.45 (−0.86, 1.68)	1.10 (0.83, 1.41)	9	0.6 (0.2, 1.1)	−0.23 (−0.70, 0.27)	0.73 (0.27, 1.45)
ABC/3TC	133	4.8 (3.9, 5.6)	0.19 (−0.83, 1.11)	1.04 (0.83, 1.26)	24	0.8 (0.5, 1.2)	0.005 (−0.44, 0.40)	1.01 (0.58, 1.61)
Other regimes	107	4.2 (3.5, 5.0)	−0.33 (−1.34, 0.66)	0.93 (0.72, 1.16)	15	0.5 (0.3, 0.8)	−0.33 (−0.72, 0.06)	0.61 (0.28, 1.10)

^*Adjusted via inverse probability weighting for age (in years, linear and quadratic terms), transmission category (heterosexual, homo/bisexual, injecting drug use, other), country of origin (Spain, other), CD4 (<350, 350–500, >500 cells/mm3), and hypertension, diabetes, chronic renal disease, cardiovascular disease, and treatment with immunosuppressants or corticosteroids.